SMT202000584T1 - Liposomi personalizzati per il trattamento delle infezioni batteriche - Google Patents
Liposomi personalizzati per il trattamento delle infezioni battericheInfo
- Publication number
- SMT202000584T1 SMT202000584T1 SM20200584T SMT202000584T SMT202000584T1 SM T202000584 T1 SMT202000584 T1 SM T202000584T1 SM 20200584 T SM20200584 T SM 20200584T SM T202000584 T SMT202000584 T SM T202000584T SM T202000584 T1 SMT202000584 T1 SM T202000584T1
- Authority
- SM
- San Marino
- Prior art keywords
- treatment
- bacterial infections
- liposomes
- tailored
- tailored liposomes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12171924 | 2012-06-14 | ||
| EP13153039 | 2013-01-29 | ||
| EP13732388.7A EP2861214B1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
| PCT/EP2013/062207 WO2013186286A1 (en) | 2012-06-14 | 2013-06-13 | Tailored liposomes for the treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000584T1 true SMT202000584T1 (it) | 2020-11-10 |
Family
ID=48703423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200584T SMT202000584T1 (it) | 2012-06-14 | 2013-06-13 | Liposomi personalizzati per il trattamento delle infezioni batteriche |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10744089B2 (enExample) |
| EP (2) | EP2861214B1 (enExample) |
| JP (2) | JP6382801B2 (enExample) |
| CN (2) | CN104602672B (enExample) |
| AU (2) | AU2013276565B2 (enExample) |
| BR (1) | BR112014031278B1 (enExample) |
| CA (1) | CA2875470C (enExample) |
| CY (1) | CY1123337T1 (enExample) |
| DK (1) | DK2861214T3 (enExample) |
| ES (1) | ES2821502T3 (enExample) |
| HR (1) | HRP20201761T1 (enExample) |
| HU (1) | HUE051761T2 (enExample) |
| LT (1) | LT2861214T (enExample) |
| PL (1) | PL2861214T3 (enExample) |
| RS (1) | RS60951B1 (enExample) |
| RU (1) | RU2672106C2 (enExample) |
| SI (1) | SI2861214T1 (enExample) |
| SM (1) | SMT202000584T1 (enExample) |
| WO (1) | WO2013186286A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2861214B1 (en) | 2012-06-14 | 2020-08-05 | Universität Bern | Tailored liposomes for the treatment of bacterial infections |
| WO2015084677A1 (en) | 2013-12-02 | 2015-06-11 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| CA3009119A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| WO2017177073A1 (en) * | 2016-04-07 | 2017-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
| DK3471732T3 (da) | 2016-06-16 | 2020-08-17 | Combioxin Sa | Liposomer til behandling af virusinfektioner |
| ES3060425T3 (en) | 2017-03-02 | 2026-03-26 | Combioxin Sa | Liposomes for inhibiting biofilm formation |
| US11344497B1 (en) * | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| KR102915698B1 (ko) * | 2018-04-17 | 2026-01-28 | 콤비옥신 에스에이 | 폐렴의 치료 |
| PT3781210T (pt) * | 2018-04-20 | 2024-10-02 | Combioxin Sa | Tratamento da hipotensão com sépsis ou choque séptico |
| CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
| EP4093458A4 (en) | 2020-01-20 | 2024-01-17 | Arytha Biosciences LLC | Devices containing cellular membrane and uses thereof |
| JP2023536833A (ja) * | 2020-07-31 | 2023-08-30 | サインパス ファルマ，インク． | サイトカイン放出及びサイトカインストームの抑制 |
| CN115054577B (zh) * | 2022-05-17 | 2024-06-21 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
| WO2026099472A1 (en) | 2024-11-08 | 2026-05-15 | Universität Bern | Liposomal compositions for treatment of inflammation |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3641247A (en) | 1970-12-14 | 1972-02-08 | Stanley Drug Products Inc | Methods of treating bacterial infections |
| WO1991004019A1 (en) * | 1989-09-12 | 1991-04-04 | The Regents Of The University Of California | Therapeutic peptides and proteins |
| NL9000207A (enExample) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| WO1993004672A1 (en) * | 1991-09-11 | 1993-03-18 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| US20050118250A1 (en) * | 2001-11-13 | 2005-06-02 | Paul Tardi | Lipid carrier compositions with enhanced blood stability |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| JP4187249B2 (ja) | 2002-03-08 | 2008-11-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プレシナプス蛋白ｐ１２０ |
| AU2003265241A1 (en) * | 2002-05-23 | 2003-12-12 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
| AU2003298738A1 (en) * | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
| WO2004087097A2 (en) * | 2003-03-31 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
| KR101462825B1 (ko) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| AU2005304914B2 (en) * | 2004-11-05 | 2012-02-16 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal camptothecin formulations |
| US20090186073A1 (en) | 2005-08-11 | 2009-07-23 | National Institute Of Advanced Industrial Science And Technology | Design of Delivery Vehicle Based On Rolling Model |
| CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
| US20080131497A1 (en) | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
| US9637515B2 (en) * | 2006-11-06 | 2017-05-02 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
| WO2011160110A1 (en) * | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
| WO2012021107A2 (en) * | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| CN102327220B (zh) * | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
| EP2861214B1 (en) | 2012-06-14 | 2020-08-05 | Universität Bern | Tailored liposomes for the treatment of bacterial infections |
| US10716756B2 (en) | 2016-06-20 | 2020-07-21 | Vivacelle Bio, Inc. | Compositions and methods for reducing reperfusion injury |
| ES3060425T3 (en) | 2017-03-02 | 2026-03-26 | Combioxin Sa | Liposomes for inhibiting biofilm formation |
| KR102915698B1 (ko) | 2018-04-17 | 2026-01-28 | 콤비옥신 에스에이 | 폐렴의 치료 |
-
2013
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en not_active Ceased
- 2013-06-13 SM SM20200584T patent/SMT202000584T1/it unknown
- 2013-06-13 HR HRP20201761TT patent/HRP20201761T1/hr unknown
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US12599558B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2861214T3 (pl) | Liposomy przystosowane do leczenia zakażeń bakteryjnych | |
| ZA201501018B (en) | Compounds for the treatment of paramoxyvirus viral infections | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| ZA201500921B (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases | |
| SG11201504813XA (en) | Mannose derivatives for treating bacterial infections | |
| PL2696890T3 (pl) | Leczenie infekcji drobnoustrojowych | |
| GB201217097D0 (en) | Treatment of bacterial infection | |
| EP2809359A4 (en) | AIR TREATMENT SYSTEM | |
| GB201212588D0 (en) | Colicins for treating bacterial infections | |
| GB201502225D0 (en) | Formation treatment system | |
| AP2015008338A0 (en) | Compounds for the treatment and prevention of retroviral infections | |
| PT2544711E (pt) | Tratamento de infeções estreptocócicas | |
| IL233486A0 (en) | Synthetic peptides for the treatment of bacterial infections | |
| ZA201306342B (en) | The treatment of viral infections | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| ZA201308116B (en) | Avian-based treatment for microbial infections | |
| ZA201308806B (en) | Liposomal vancomycin for the treatment of mrsa infections | |
| PT2861214T (pt) | Lipossomas adaptados para o tratamento de infeções bacterianas | |
| EP2670407A4 (en) | TREATMENT OF BACTERIAL INFECTIONS | |
| AU2012904839A0 (en) | Phage therapy for the treatment of MRSA infections | |
| AP2015008270A0 (en) | Preparation for the treatment of tuberculosis | |
| GB2515669B (en) | Bacterial vaccine | |
| GB201212715D0 (en) | Treatment of fungal infections | |
| AU2012900513A0 (en) | Avian-Based Treatment | |
| GB201301722D0 (en) | Quantifcation of bacteria |